US Stem Cell IncOver The Counter Market:USRM
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
US Stem Cell Inc | 64.2K | 0.0x | --- |
Trex Wind-Down Inc | 340.0 | 0.0x | --- |
RegeneRx Biopharmaceuticals Inc | 2.1K | 0.0x | --- |
Multicell Technologies Inc | 5.0K | 0.0x | --- |
Sangui BioTech International Inc | 314.9K | -2.5x | --- |
RightSmile Inc | 30.0K | 0.0x | --- |
Company Information
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
Contact Information
- Headquarters
- 1560 Sawgrass Corporate Pkwy, 4Th FloorSUNRISE, FL, United States 33323
- Phone
- 954-835-1500
- Fax
- 954-845-9976
Executives
- Non-Executive Chairman of the Board
- Mark Borman
- Chairman Emeritus
- William Murphy
- President, Chief Executive Officer, Chief Financial Officer, Director
- Mike Tomas
- Director
- Sheldon Anderson
- Director
- Gregory Knutson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $64.2K |
|---|---|
Revenue (TTM) | $82.1K |
Shares Outstanding | 641.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.29 |
EPS | $0.00 |
Book Value | $-0.02 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,642.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
